Sun Pharma gains on better outlook for key drug
Analysts expect generic doxycycline to contribute around US$60-80 million in sales in FY14 for Sun Pharma.
August 24, 2013 / 11:55 IST
Sun Pharmaceutical Industries is up 1 percent after a competitor raised its revenue guidance, citing strong sale of a generic antibiotic also sold by Sun Pharma.
Hikma Pharmaceuticals Plc
on Wednesday raised its full-year revenue forecast for the third time in four months, riding on strong sales of generic antibiotic doxycycline, a drug used to prevent and treat malaria and other infections.
Analysts expect generic doxycycline to contribute around USD 60-80 million in sales in FY14 for Sun Pharma. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
